诊断时血清可溶性白细胞介素-2受体超高水平预示血管免疫母细胞性T细胞淋巴瘤预后不良。

Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.

作者信息

Shiratori Souichi, Kosugi-Kanaya Mizuha, Shigematsu Akio, Kobayashi Hajime, Yamamoto Satoshi, Kobayashi Naoki, Iwasaki Hiroshi, Mori Akio, Kunieda Yasuyuki, Yutaka Tsutsumi, Kurosawa Mitsutoshi, Kakinoki Yasutaka, Endo Tomoyuki, Kondo Takeshi, Hashino Satoshi, Teshima Takanori

机构信息

a Department of Hematology , Hokkaido University Graduate School of Medicine , Sapporo , Japan.

b Department of Internal Medicine , Hakodate Municipal Hospital , Hakodate , Japan.

出版信息

Leuk Lymphoma. 2015;56(9):2592-7. doi: 10.3109/10428194.2014.1001985. Epub 2015 Feb 24.

DOI:10.3109/10428194.2014.1001985

PMID:25563559

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of non-Hodgkin lymphoma and displays an aggressive clinical course with poor outcome. To identify prognostic factors for AITL, we retrospectively analyzed 36 patients with AITL. The median age was 74 years with 83% of the patients having advanced stage. Eighty-three percent received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like chemotherapies, resulting in an overall response rate of 63%. With a median follow-up of 9 years, the estimated overall survival at 5 years was 33.3%. Median serum level of soluble interleukin-2 receptor (sIL-2R) was 5615 U/mL at diagnosis, and over 10 000 U/mL of sIL-2R was identified as a significant poor prognostic factor, independent of the International Prognostic Index, Prognostic Index for peripheral T-cell lymphoma and Prognostic index for AITL (hazard ratio [HR], 4.42; 95% confidence interval [CI], 1.49-13.11; log-rank, p < 0.01). Our study shows that an ultra-high level of serum sIL-2R at diagnosis is a significant poor prognostic biomarker for AITL.

摘要

血管免疫母细胞性T细胞淋巴瘤（AITL）是一种罕见的非霍奇金淋巴瘤亚型，临床病程呈侵袭性，预后较差。为了确定AITL的预后因素，我们回顾性分析了36例AITL患者。中位年龄为74岁，83%的患者处于晚期。83%的患者接受了类似CHOP（环磷酰胺、阿霉素、长春新碱、泼尼松龙）的化疗，总缓解率为63%。中位随访9年，5年总生存率估计为33.3%。诊断时可溶性白细胞介素-2受体（sIL-2R）的中位血清水平为5615 U/mL，sIL-2R超过10000 U/mL被确定为一个显著的不良预后因素，独立于国际预后指数、外周T细胞淋巴瘤预后指数和AITL预后指数（风险比[HR]，4.42；95%置信区间[CI]，1.49-13.11；对数秩检验，p<0.01）。我们的研究表明，诊断时血清sIL-2R的超高水平是AITL的一个显著不良预后生物标志物。